Mini Sentinel Data Covers 126 Million Patients; FDA Weighing Potential Uses For Drug Industry
Executive Summary
With the recent addition of claims data from two major insurance companies, the FDA postmarketing drug safety surveillance pilot project known as Mini Sentinel has already exceeded its statutory goal of gaining access to electronic health care data for 100 million individuals by July 12, 2012.
You may also be interested in...
Reagan-Udall, Pfizer Testing Ways To Tap Sentinel Network Without FDA
A pilot project operated by the Reagan-Udall Foundation and funded by Pfizer will evaluate ways drug companies can use FDA’s Sentinel electronic data network to conduct independent post-market safety surveillance.
Reimbursing Rare Disease Drugs: Getting Away From High Co-Pays
Former CMS Administrator Mark McClellan argues that drugs for rare disease should not be on the high-cost-sharing specialty tier of Medicare Part D formularies. “High value” therapies deserve low co-pays, he argues.
Mini Sentinel Alleviates FDA Concern Over Pradaxa Bleeding Issue
Data from the pilot program a “driving factor” in the agency’s decision against changing its recommendations for the blood thinner following reports of increased serious bleeding events.